These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 36697790)
21. Overcoming tnf-alpha and cddp resistance of a human ovarian-cancer cell-line (c30) by treatment with buthionine sulfoximine in combination with tnf-alpha and or cddp. Mizutani Y; Bonavida B Int J Oncol; 1993 Aug; 3(2):229-35. PubMed ID: 21573353 [TBL] [Abstract][Full Text] [Related]
22. [Effect of D,L-buthionine-S,R-sulfoximine on the ratio of glutathione forms and the growth of tatar buckwheat calli]. Nigmatullina LR; Rumiantseva NI; Kostiukova IuA Ontogenez; 2014; 45(1):50-62. PubMed ID: 25720265 [TBL] [Abstract][Full Text] [Related]
23. Overcoming tumor necrosis factor-alpha resistance of human renal and ovarian carcinoma cells by combination treatment with buthionine sulfoximine and tumor necrosis factor-alpha. Role of tumor necrosis factor-alpha mRNA down-regulation in tumor cell sensitization. Mizutani Y; Yoshida O Cancer; 1994 Feb; 73(3):730-7. PubMed ID: 8299097 [TBL] [Abstract][Full Text] [Related]
24. Depletion of glutathione by L-buthionine sulfoximine does not promote inactivation of myo-inositol transport in cultured bovine lens epithelial cells. Cammarata PR; Tse D; Yorio T Curr Eye Res; 1991 Apr; 10(4):321-30. PubMed ID: 1676962 [TBL] [Abstract][Full Text] [Related]
25. Markedly decreased expression of glutathione S-transferase pi gene in human cancer cell lines resistant to buthionine sulfoximine, an inhibitor of cellular glutathione synthesis. Yokomizo A; Kohno K; Wada M; Ono M; Morrow CS; Cowan KH; Kuwano M J Biol Chem; 1995 Aug; 270(33):19451-7. PubMed ID: 7642628 [TBL] [Abstract][Full Text] [Related]
27. An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity Mayr J; Heffeter P; Groza D; Galvez L; Koellensperger G; Roller A; Alte B; Haider M; Berger W; Kowol CR; Keppler BK Chem Sci; 2017 Mar; 8(3):2241-2250. PubMed ID: 28507680 [TBL] [Abstract][Full Text] [Related]
28. Overcoming Cancer Cell Drug Resistance by a Folic Acid Targeted Polymeric Conjugate of Buthionine Sulfoximine. Cilurzo F; Cristiano MC; Da Pian M; Cianflone E; Quintieri L; Paolino D; Pasut G Anticancer Agents Med Chem; 2019; 19(12):1513-1522. PubMed ID: 31241440 [TBL] [Abstract][Full Text] [Related]
29. Minimal ovarian upregulation of glutamate cysteine ligase expression in response to suppression of glutathione by buthionine sulfoximine. Hoang YD; Avakian AP; Luderer U Reprod Toxicol; 2006 Feb; 21(2):186-96. PubMed ID: 16183247 [TBL] [Abstract][Full Text] [Related]
30. Glutathione depletion by buthionine sulfoximine induces DNA deletions in mice. Reliene R; Schiestl RH Carcinogenesis; 2006 Feb; 27(2):240-4. PubMed ID: 16162646 [TBL] [Abstract][Full Text] [Related]
31. Selective and synergistic activity of L-S,R-buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione-S-transferase. Fruehauf JP; Zonis S; al-Bassam M; Kyshtoobayeva A; Dasgupta C; Milovanovic T; Parker RJ; Buzaid AC Pigment Cell Res; 1997 Aug; 10(4):236-49. PubMed ID: 9263331 [TBL] [Abstract][Full Text] [Related]
32. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. O'Dwyer PJ; Hamilton TC; LaCreta FP; Gallo JM; Kilpatrick D; Halbherr T; Brennan J; Bookman MA; Hoffman J; Young RC; Comis RL; Ozols RF J Clin Oncol; 1996 Jan; 14(1):249-56. PubMed ID: 8558205 [TBL] [Abstract][Full Text] [Related]
33. Glutathione depletion by DL-buthionine-SR-sulfoximine (BSO) potentiates X-ray-induced chromosome lesions after liquid holding recovery. Bertsche U; Schorn H Radiat Res; 1986 Mar; 105(3):351-69. PubMed ID: 3754339 [TBL] [Abstract][Full Text] [Related]
34. Effects of the long-term depletion of reduced glutathione in mice administered L-buthionine-S,R-sulfoximine. Sun JD; Ragsdale SS; Benson JM; Henderson RF Fundam Appl Toxicol; 1985 Oct; 5(5):913-9. PubMed ID: 2866140 [TBL] [Abstract][Full Text] [Related]
35. Buthionine sulfoximine inhibition of cystine uptake and glutathione biosynthesis in human lung carcinoma cells. Brodie AE; Reed DJ Toxicol Appl Pharmacol; 1985 Mar; 77(3):381-7. PubMed ID: 3975906 [TBL] [Abstract][Full Text] [Related]
36. Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis. Lewis-Wambi JS; Kim HR; Wambi C; Patel R; Pyle JR; Klein-Szanto AJ; Jordan VC Breast Cancer Res; 2008; 10(6):R104. PubMed ID: 19061505 [TBL] [Abstract][Full Text] [Related]
37. Schisandrin B-induced increase in cellular glutathione level and protection against oxidant injury are mediated by the enhancement of glutathione synthesis and regeneration in AML12 and H9c2 cells. Chiu PY; Ko KM Biofactors; 2006; 26(4):221-30. PubMed ID: 17119269 [TBL] [Abstract][Full Text] [Related]
38. Oxaliplatin-Based Platinum(IV) Prodrug Bearing Toll-like Receptor 7 Agonist for Enhanced Immunochemotherapy. Tang L; Cai D; Qin M; Lu S; Hu MH; Ruan S; Jin G; Wang Z ACS Omega; 2020 Jan; 5(1):726-734. PubMed ID: 31956823 [TBL] [Abstract][Full Text] [Related]
39. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow. Ono K; Shrieve DC J Natl Cancer Inst; 1987 Oct; 79(4):811-5. PubMed ID: 3477662 [TBL] [Abstract][Full Text] [Related]